Department of Neurological Sciences, IRCCS Neuromed, Via Atinense, Pozzilli, (IS), Italy.
UPMC San Pietro FBF, Radiotherapy Center, Rome, Italy.
Radiat Oncol. 2017 Jun 19;12(1):101. doi: 10.1186/s13014-017-0841-9.
The incidence of brain tumors in the elderly population has increased over the last few decades. Current treatment includes surgery, radiotherapy and chemotherapy, but the optimal management of older patients with brain tumors remains a matter of debate, since aggressive radiation treatments in this population may be associated with high risks of neurological toxicity and deterioration of quality of life. For such patients, a careful clinical status assessment is mandatory both for clinical decision making and for designing randomized trials to adequately evaluate the optimal combination of radiotherapy and chemotherapy.Several randomized studies have demonstrated the efficacy and safety of chemotherapy for patients with glioblastoma or lymphoma; however, the use of radiotherapy given in association with chemotherapy or as salvage therapy remains an effective treatment option associated with survival benefit. Stereotactic techniques are increasingly used for the treatment of patients with brain metastases and benign tumors, including pituitary adenomas, meningiomas and acoustic neuromas. Although no randomized trials have proven the superiority of SRS over other radiation techniques in older patients with brain metastases or benign brain tumors, data extracted from recent randomized studies and large retrospective series suggest that SRS is an effective approach in such patients associated with survival advantages and toxicity profile similar to those observed in young adults. Future trials need to investigate the optimal radiation techniques and dose/fractionation schedules in older patients with brain tumors with regard to clinical outcomes, neurocognitive function, and quality of life.
过去几十年中,老年人群体中的脑肿瘤发病率有所增加。目前的治疗方法包括手术、放疗和化疗,但对于老年脑肿瘤患者的最佳管理仍然存在争议,因为在这一人群中进行积极的放疗可能与较高的神经毒性和生活质量恶化风险相关。对于此类患者,必须进行仔细的临床状况评估,以便做出临床决策,并设计随机试验来充分评估放疗和化疗的最佳组合。
多项随机研究已经证明了化疗对于胶质母细胞瘤或淋巴瘤患者的疗效和安全性;然而,联合化疗或作为挽救性治疗的放疗的使用仍然是一种有效的治疗选择,与生存获益相关。立体定向技术越来越多地用于治疗脑转移瘤和良性肿瘤患者,包括垂体腺瘤、脑膜瘤和听神经瘤。虽然没有随机试验证明在老年脑转移瘤或良性脑肿瘤患者中,SRS 优于其他放疗技术,但从最近的随机研究和大型回顾性系列中提取的数据表明,SRS 是一种有效的治疗方法,在这些患者中具有生存优势,并且毒性特征与在年轻成年人中观察到的相似。未来的试验需要研究在脑肿瘤老年患者中,关于临床结果、神经认知功能和生活质量方面,最佳的放疗技术和剂量/分割方案。